
<800> Hazardous Drugs—Handling in Healthcare Settings

Type of Posting: Notice of Intent to Revise

Posting Date: 01–May–2020

Target Official Date: 01–Jul–2020; Revision Bulletin

Expert Committee: Compounding

In accordance with section 7.04 (c) of the 2015–2020 Rules and Procedures of the Council of Experts, this is to provide notice that Compounding Expert Committee (CMP EC) intends to publish a Revision Bulletin to clarify that for the purposes of General Chapter <800> *Hazardous Drugs—Handling in Healthcare Settings*, the term “antineoplastic” is intended to refer to antineoplastic hazardous drugs (HDs) included in Table 1 of the most current NIOSH list.

In the 2020 NIOSH List of Hazardous Drugs in Healthcare Settings that is published for [public comment](#), antineoplastic HDs have been included in Table 1 and 2, whereas in previous NIOSH lists, antineoplastic HDs were only included in Table 1. The CMP EC intends to revise <800> to clarify that for the purposes of the <800>, the requirements for antineoplastic HDs apply only to those in Table 1 of the NIOSH list. The CMP EC intends to add the following sentence to 2. List of Hazardous Drugs.

For the purposes of this chapter, the term antineoplastic only refers to antineoplastic drugs included in Table 1 of the most current NIOSH list.

Should you have any questions, please contact Tiffany Chan, Associate Scientific Liaison, Healthcare Quality and Safety (CompoundingSL@usp.org).

